Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Report

Global and Region Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 02, 2022
  • PAGES：169
  • REPORT CODE：GMM995678
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Neuromyelitis Optica Spectrum Disorder (NMOSD) market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Neuromyelitis Optica Spectrum Disorder (NMOSD)market, defines the market attractiveness level of Neuromyelitis Optica Spectrum Disorder (NMOSD) market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Neuromyelitis Optica Spectrum Disorder (NMOSD) industry, describes the types of Neuromyelitis Optica Spectrum Disorder (NMOSD) market, the applications of major players and the market size, and deeply analyzes the current situation of the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market and the development prospects and opportunities of Neuromyelitis Optica Spectrum Disorder (NMOSD) industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market in Chapter 13.

    By Player:

    • Cour Pharmaceutical

    • Nihon Pharmaceutical

    • Alexion Pharmaceuticals

    • Bio-Thera Solutions

    • Bionure

    • Opexa Therapeutics

    • Boston Pharmaceuticals

    • Lundbeck

    • F Hoffmann-La Roche Ltd

    • Harbour BioMed

    • TG Therapeutics

    • RemeGen

    By Type:

    • Intravenous

    • Oral

    • Subcutaneous

    • Others

    By End-User:

    • Hospital

    • Clinic

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Analysis and Outlook to 2022

    • 7.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)

    • 7.2 United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)

    • 7.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)

    • 7.4 China Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)

    • 7.5 Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)

    • 7.6 India Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)

    • 7.7 South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption (2017-2022)

    8 Region and Country-wise Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Analysis and Outlook to 2028

    • 8.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)

    • 8.2 United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)

    • 8.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)

    • 8.4 China Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)

    • 8.5 Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)

    • 8.6 India Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)

    • 8.7 South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast (2022-2028)

    9 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Outlook by Types and Applications to 2022

    • 9.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Intravenous Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Oral Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Subcutaneous Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Outlook by Types and Applications to 2028

    • 10.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Intravenous Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Oral Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Subcutaneous Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Competitive Analysis

    • 14.1 Cour Pharmaceutical

      • 14.1.1 Cour Pharmaceutical Company Details

      • 14.1.2 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • 14.2 Nihon Pharmaceutical

      • 14.2.1 Nihon Pharmaceutical Company Details

      • 14.2.2 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • 14.3 Alexion Pharmaceuticals

      • 14.3.1 Alexion Pharmaceuticals Company Details

      • 14.3.2 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • 14.4 Bio-Thera Solutions

      • 14.4.1 Bio-Thera Solutions Company Details

      • 14.4.2 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • 14.5 Bionure

      • 14.5.1 Bionure Company Details

      • 14.5.2 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • 14.6 Opexa Therapeutics

      • 14.6.1 Opexa Therapeutics Company Details

      • 14.6.2 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • 14.7 Boston Pharmaceuticals

      • 14.7.1 Boston Pharmaceuticals Company Details

      • 14.7.2 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • 14.8 Lundbeck

      • 14.8.1 Lundbeck Company Details

      • 14.8.2 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • 14.9 F Hoffmann-La Roche Ltd

      • 14.9.1 F Hoffmann-La Roche Ltd Company Details

      • 14.9.2 F Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 F Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • 14.10 Harbour BioMed

      • 14.10.1 Harbour BioMed Company Details

      • 14.10.2 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • 14.11 TG Therapeutics

      • 14.11.1 TG Therapeutics Company Details

      • 14.11.2 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • 14.12 RemeGen

      • 14.12.1 RemeGen Company Details

      • 14.12.2 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Neuromyelitis Optica Spectrum Disorder (NMOSD)

    • Figure Neuromyelitis Optica Spectrum Disorder (NMOSD) Picture

    • Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption by Country (2017-2022)

    • Figure United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)

    • Table Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)

    • Figure China Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)

    • Figure Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)

    • Figure India Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)

    • Figure South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption and Growth Rate (2017-2022)

    • Figure Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast by Country (2022-2028)

    • Figure United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Intravenous Consumption and Growth Rate (2017-2022)

    • Figure Global Oral Consumption and Growth Rate (2017-2022)

    • Figure Global Subcutaneous Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Intravenous Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oral Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Subcutaneous Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Export by Region (Top 5 Countries) (2017-2028)

    • Table Cour Pharmaceutical (Foundation Year, Company Profile and etc.)

    • Table Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • Table Nihon Pharmaceutical (Foundation Year, Company Profile and etc.)

    • Table Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • Table Alexion Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • Table Bio-Thera Solutions (Foundation Year, Company Profile and etc.)

    • Table Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • Table Bionure (Foundation Year, Company Profile and etc.)

    • Table Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • Table Opexa Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • Table Boston Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • Table Lundbeck (Foundation Year, Company Profile and etc.)

    • Table Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • Table F Hoffmann-La Roche Ltd (Foundation Year, Company Profile and etc.)

    • Table F Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

    • Table F Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • Table Harbour BioMed (Foundation Year, Company Profile and etc.)

    • Table Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • Table TG Therapeutics (Foundation Year, Company Profile and etc.)

    • Table TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

    • Table TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service

    • Table RemeGen (Foundation Year, Company Profile and etc.)

    • Table RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Sales, Price, Value and Gross Profit (2017-2022)

    • Table RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US